On Apr, 16 Intersect ENT, Inc. (XENT) Reached 1-Year High at $40.80

April 16, 2018 - By Robert Reynolds

Intersect ENT, Inc. (NASDAQ:XENT) Corporate Logo

Intersect ENT, Inc. (NASDAQ:XENT) broke into one-year high with $43.25 price target or 6.00 % above the last $40.80 share price. It was published on Apr, 16 according to Barchart.com Intersect ENT, Inc. (NASDAQ:XENT) has $1.22B market cap. At $43.25 stock price target, the company valuation changes by $72.96M more.

XENT reached $40.8 on during the last trading session after $1.25 change.Intersect ENT, Inc. has volume of 227,774 shares. Since April 16, 2017 XENT has risen 124.86% and is uptrending. XENT outperformed the S&P500 by 113.31%.

Analysts await Intersect ENT, Inc. (NASDAQ:XENT) to report earnings on May, 1. They expect $-0.23 EPS, 0.00 % or $0.00 from last year’s $-0.23 per share. After $-0.11 actual EPS reported by Intersect ENT, Inc. for the previous quarter, Wall Street now forecasts 109.09 % negative EPS growth.

Intersect ENT, Inc. (NASDAQ:XENT) Ratings Coverage

In total 3 analysts cover Intersect ENT (NASDAQ:XENT). “Buy” rating has 2, “Sell” are 0, while 1 are “Hold”. 67% are bullish. 4 are the (NASDAQ:XENT)’s analyst reports since November 6, 2017 according to StockzIntelligence Inc. The company rating was upgraded by JP Morgan on Tuesday, January 2. On Thursday, January 4 the firm earned “Buy” rating by Canaccord Genuity. In Wednesday, December 6 report Canaccord Genuity maintained it with “Buy” rating and $36.0 target.

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States.The company has $1.22 billion market cap. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.Last it reported negative earnings. The firm is also developing RESOLVE, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting.

Intersect ENT, Inc. (NASDAQ:XENT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: